Liver transplantation and combined liver‐heart transplantation in patients with familial amyloid polyneuropathy: A single‐center experience

Ana‐Paula Barreiros, Felix Post, Maria Hoppe‐Lotichius, Reinhold P. Linke, Christian F. Vahl, Hans‐Joachim Schäfers, Peter R. Galle, Gerd Otto – 12 January 2010 – Liver transplantation (LT) is the only curative option for patients with familial amyloid polyneuropathy (FAP) at present. Twenty patients with FAP underwent LT between May 1998 and June 2007. Transthyretin mutations included predominantly the Val30Met mutation but also 10 other mutations.

Microbial epidemiology and outcome of bloodstream infections in liver transplant recipients: An analysis of 259 episodes

Frédéric Bert, Beatrice Larroque, Catherine Paugam‐Burtz, Sylvie Janny, Francois Durand, Fédérica Dondero, Dominique‐Charles Valla, Jacques Belghiti, Richard Moreau, Marie‐Hélène Nicolas‐Chanoine – 12 January 2010 – Bloodstream infections (BSIs) are a major cause of mortality in liver transplant recipients. The incidence, microbiology, and outcome of BSIs in the first year after liver transplantation were analyzed in 704 patients who underwent transplantation at a single center between 1997 and 2007. BSIs occurred in 205 (29.1%) of the 704 patients.

Long‐term outcome of patients with hereditary hemorrhagic telangiectasia and severe hepatic involvement after orthotopic liver transplantation: A single‐center study

Sophie Dupuis‐Girod, Anne‐Laure Chesnais, Isabelle Ginon, Jérôme Dumortier, Jean‐Christophe Saurin, Gérard Finet, Evelyne Decullier, Denis Marion, Henri Plauchu, Olivier Boillot – 12 January 2010 – Hepatic involvement occurs in up to 74% of patients with hereditary hemorrhagic telangiectasia (HHT) and is characterized by a spectrum of arteriovenous malformations. Three different types of intrahepatic shunting may be present: hepatic artery to hepatic veins, hepatic artery to portal vein, and portal vein to hepatic vein.

Long‐term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis

Sanjay Y. Bangarulingam, Einar Bjornsson, Felicity Enders, Emily G. Barr Fritcher, Gregory Gores, Kevin C. Halling, Keith D. Lindor – 23 December 2009 – Patients with primary sclerosing cholangitis (PSC) are at increased risk for developing cholangiocarcinoma (CCA). Fluorescence in situ hybridization (FISH) is a cytological test designed to enhance early CCA diagnosis. The long‐term outcome of PSC patients with a positive FISH test (polysomy, trisomy/tetrasomy) are unclear.

Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease

Lauren N. Bell, Janice L. Theodorakis, Raj Vuppalanchi, Romil Saxena, Kerry G. Bemis, Mu Wang, Naga Chalasani – 23 December 2009 – Nonalcoholic fatty liver disease (NAFLD), ranging from relatively benign simple steatosis to progressive nonalcoholic steatohepatitis (NASH) and fibrosis, is an increasingly common chronic liver disease. Liver biopsy is currently the only reliable tool for staging the subtypes of NAFLD; therefore, noninvasive serum biomarkers for evaluation of liver disease and fibrosis are urgently needed.

Alcoholic liver disease

Robert S. O'Shea, Srinivasan Dasarathy, Arthur J. McCullough, Practice Guideline Committee of the American Association for the Study of Liver Diseases and the Practice Parameters Committee of the American College of Gastroenterology – 23 December 2009

Long‐term efficacy of tenofovir monotherapy for hepatitis B virus‐monoinfected patients after failure of nucleoside/nucleotide analogues

Florian van Bömmel, Robert A. de Man, Heiner Wedemeyer, Katja Deterding, Jörg Petersen, Peter Buggisch, Andreas Erhardt, Dietrich Hüppe, Kerstin Stein, Jörg Trojan, Christoph Sarrazin, Wulf O. Böcher, Ulrich Spengler, Hermann E. Wasmuth, Jurrien G.P.

Subscribe to